BPH Global finalises Project Giddy-Up formulation, advances toward efficacy testing
BPH Global has completed the final formulation of its proprietary seaweed-based men’s health supplement under Project Giddy-Up, marking the transition from development into validation phase. The BPH Global Project Giddy-Up Update confirms all ingredients and their respective proportions have been locked down, positioning the project to advance into planned cell-based efficacy testing.
The announcement comes as the company has received a draft services agreement from Temasek Innovation Holdings Pte Ltd (TPIH), an operating entity of Temasek Polytechnic in Singapore, for a proposed two-stage efficacy testing program. BPH is currently reviewing the agreement with a view to execution in the near term.
The completion of formulation development represents a de-risking milestone for the project. With the product composition now finalised, BPH can progress into validation studies with a credible third-party research partner. The company’s regulatory pathway toward listing on the Australian Register of Therapeutic Goods (ARTG) as a TGA-listed complementary medicine (AUST L) remains unchanged.
When big ASX news breaks, our subscribers know first
What is cell-based efficacy testing and why does it matter?
Cell-based efficacy testing refers to laboratory testing using human or animal cells to measure a product’s biological activity before advancing to clinical trials. This type of testing is a standard step in supplement and pharmaceutical development, designed to demonstrate a product’s mechanism of action in a controlled environment.
For ASX: BP8, partnering with TPIH provides access to established research infrastructure and third-party validation. TPIH operates under Temasek Polytechnic, a recognised educational and research institution in Singapore, lending credibility to the validation process.
The proposed two-stage testing program will assess the supplement’s efficacy at a cellular level, providing data to support both the commercial case and the regulatory submission for TGA listing. This independent validation strengthens the product’s scientific foundation ahead of its planned entry into the men’s health supplement market.
Next steps and regulatory pathway
BPH has outlined its immediate next steps as the project progresses into the validation phase:
-
Finalising and executing the services agreement with TPIH
-
Commencing detailed liaison and coordination with TPIH to facilitate implementation of the R&D work program
-
Conducting the planned cell-based efficacy testing program
The company confirmed its regulatory strategy remains unchanged. BPH continues to target listing of the product on the ARTG as a TGA-listed complementary medicine under the AUST L category. This classification is appropriate for complementary medicines containing ingredients with an established history of use and an acceptable level of safety.
The TGA pathway provides a structured route to market for the supplement. AUST L listing requires sponsors to hold evidence supporting product claims, though the TGA does not evaluate this evidence before listing. The cell-based efficacy testing being conducted through TPIH forms part of the evidence base BPH will compile to support its ARTG application.
The next major ASX story will hit our subscribers first
What this means for BPH Global shareholders
The completion of formulation development closes out the early-stage development phase for Project Giddy-Up. With the product composition now locked down, the project moves into validation, where the focus shifts to demonstrating efficacy through controlled testing.
The engagement with TPIH provides BPH with access to credible third-party research capabilities. Independent validation studies strengthen the product’s scientific credentials and support the regulatory case for TGA listing. This partnership reduces execution risk by utilising established research infrastructure rather than requiring BPH to build internal testing capabilities.
The company noted further updates will be provided as R&D milestones are achieved. Investors can expect progress reports as the TPIH services agreement is executed and efficacy testing commences. The BPH Global Project Giddy-Up Update positions the project on a defined pathway toward commercialisation in the men’s health supplement market, with regulatory and validation milestones now clearly outlined.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements break across ASX healthcare and biotech sectors.